RE:Antibody-Drug-Conjugate (ADC) company reports patient death November 2022 - "Antibody–drug conjugates (ADCs) may increase the risk of sepsis in cancer patients, leading to high mortality."
"We identified that 973 of 2,441 (39.9%) cases had acute myeloid leukemia (AML), and 766 of 2613 (29.3%) cases on ADCs died during therapy. Time-to-onset analysis indicated ADC-related sepsis is prone to occur within a month after administration. Co-administration of ADCs with colony-stimulating factors, proton pump inhibitors, H2-receptor antagonists, or CYP3A4/5 inhibitors showed to synergistically increase the risk of sepsis-related toxicities.
https://www.frontiersin.org/articles/10.3389/fphar.2022.967017/full